Corneal dystrophy

This study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…

This study compares two types of corneal transplant surgery (UT-DSAEK and DMEK) in 160 people with Fuchs dystrophy, a condition that clouds the cornea. It also tests whether a drug called rho-kinase inhibitor can reduce loss of important eye cells after surgery. The goal is to fi…

This early-stage trial tests whether injecting cultured corneal endothelial cells into the eye can repair damaged corneas and improve vision. Twelve adults with corneal swelling and poor eyesight received a single injection of donor cells grown in a lab. The goal is to see if the…

This phase 2 study tests the drug sirolimus (rapamycin) in 7 people with idiopathic multicentric Castleman disease who have not improved with standard therapy. The goal is to see if sirolimus can improve symptoms like fatigue, fever, and night sweats, and shrink enlarged lymph no…

This phase II trial tests the drug rituximab (Rituxan) as a first treatment for multicentric Castleman disease, a rare immune disorder, in 15 adults in Malawi. Some high-risk patients also receive etoposide. The study aims to see if rituximab is safe and works better than standar…

This study aimed to compare how corneas with Fuchs endothelial corneal dystrophy (FECD) and healthy corneas swell and recover after wearing a contact lens for three hours. Researchers planned to measure corneal thickness before and after the lens was removed, tracking swelling an…

This study looks at whether corneas from donors with diabetes work as well as those from donors without diabetes after a specific type of corneal transplant called DMEK. Researchers will track 570 participants for 5 years to measure cell loss and overall transplant success. The g…

This study offers free vision screenings to underserved adults over 40 living in affordable housing in Harlem and Washington Heights. The goal is to find eye problems like glaucoma, cataracts, and diabetic retinopathy early and connect people with follow-up care. About 749 partic…